An Open-Label Study of Once-Daily Oral Administration of Esomeprazole 40 mg in Patients With Symptoms of Gastroesophageal Reflux Disease (GERD)
Information source: AstraZeneca
Information obtained from ClinicalTrials.gov on December 31, 2007
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: GERD
Intervention: Esomeprazole (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: AstraZeneca Official(s) and/or principal investigator(s):
AstraZeneca Nexium Medical Sciences Director, MD, Study Director, Affiliation: AstraZeneca
Summary
The purpose of this study is to evaluate whether there is a difference in proportion of
patients with resolution of heartburn and other symptoms related to gastroesophageal reflux
disease (GERD) after four weeks of treatment with esomeprazole (NEXIUM®) in those subjects
with Erosive Esophagitis (EE) and those without EE.
Clinical Details
Official title: An Open-Label Study of Once-Daily Oral Administration of Esomeprazole 40 mg in Patients With Symptoms of Gastroesophageal Reflux Disease (GERD) to Investigate the Relationship Between the Presence of Erosive Esophagitis (EE) at Baseline and Heartburn Resolution After 4 Weeks of Treatment
Study design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study
Primary outcome: The outcome variable will be the percentage of patients with heartburn resolution stratified by the presence or absence of EE
Secondary outcome: The outcome variables will be resolution of acid regurgitation, dysphagia, and epigastric pain symptoms after 2 and 4 weeks of treatment.The outcome variable will be the resolution of heartburn after 2 weeks of treatment. The outcome variables will be the presence or absence of EE at baseline and the resolution of heartburn at the end of the 4-week treatment period. The outcome variable used for this objective will be the percentage of endoscoped patients with EE (LA Classification Grades A-D) at baseline. Safety variables that will be measured and tabulated include adverse events, laboratory evaluations, physical exams, and vital signs.
Eligibility
Minimum age: 18 Years.
Maximum age: 70 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
Symptoms of GERD as defined in this protocol: Heartburn (severity of mild, moderate or
severe) 2 or more times in the 7 days prior to the Screening visit (Visit 1) and, on
average, at least 2 times per week over the past 3 months.
Male or female, 18 to 70 years old, inclusive.
Non-pregnant, non-lactating female patients. Female patients must be postmenopausal,
surgically sterile, or using a medically acceptable form of birth control, as determined by
the investigator. Females of childbearing potential must agree to continue using an
acceptable form of birth control throughout the conduct of the study.
Negative urine pregnancy test for females of childbearing potential.
Willingness to adhere to all protocol requirements.
Exclusion Criteria:
Previous enrollment in the present study.
Significant clinical illness within 2 weeks prior to the first dose of study medication or
a significant illness during the study.
Use of a PPI, including PRILOSEC OTC®, within 21 days of Screening (Visit 1) or at anytime
during the study (Visit 1 through Visit 4).
Daily therapy with an H2 RA within 14 days of Screening (Visit 1): eg, ranitidine
(ZANTAC®), cimetidine (TAGAMET®), nizatidine (AXID®), famotidine (PEPCID®) (occasional use;
ie, less than daily, is permitted).
Use of H2 RAs at any frequency are prohibited throughout the entire study (Visit 1 through
Visit 4).
A history of gastric or esophageal surgery (including, but not limited to, Nissen
fundoplication and bariatric surgery), except for simple closure of a perforated ulcer or
procedures that would not affect the study as determined by the Clinical Study Team
physician at AstraZeneca.
Clinically significant gastrointestinal (GI) bleeding (eg, melena, frank hematochezia)
within 3 days of Screening (Visit 1) or noted at the time of baseline EGD.
Non-acid related etiologies of esophagitis (eg, pill-induced, caustic ingestion or
eosinophilic esophagitis).
Generalized bleeding disorders resulting from hemorrhagic diathesis (such as abnormalities
in clotting factors or platelets).
Locations and Contacts
Research Site, Mobile, Alabama, United States
Research Site, Alabaster, Alabama, United States
Research Site, Tucson, Arizona, United States
Research Site, North Little Rock, Arkansas, United States
Research Site, Orange, California, United States
Research Site, Torrance, California, United States
Research Site, Anaheim, California, United States
Research Site, Ocoee, Florida, United States
Research Site, Zephyrhills, Florida, United States
Research Site, Miami, Florida, United States
Research Site, Tampa, Florida, United States
Research Site, Arlington Heights, Illinois, United States
Research Site, New Orleans, Louisiana, United States
Research Site, Shreveport, Louisiana, United States
Research Site, Hollywood, Maryland, United States
Research Site, Elkin, North Carolina, United States
Research Site, Oklahoma City, Oklahoma, United States
Research Site, Chattanooga, Tennessee, United States
Research Site, Knoxville, Tennessee, United States
Research Site, Houston, Texas, United States
Research Site, Austin, Texas, United States
Research Site, Salt Lake City, Utah, United States
Research Site, Ogden, Utah, United States
Research Site, Christiansburg, Virginia, United States
Research Site, Norfolk, Virginia, United States
Additional Information
Starting date: October 2005
Last updated: August 15, 2007
|
